Description: In today’s market of post-pandemic consolidation and org chart streamlining, we’ve observed significant changes to actuarial career development and advancement opportunities. But, those changes aren’t occurring in equal measures across the arc of the actuarial career. Our focus is on the impact felt by experienced reinsurance actuaries.

Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.

Description: Reunite with members and non-members in the China actuarial community to discuss recent topics and related issues in areas such as macroeconomic sharing, IFRS 17, product strategy, cross-border communication and discussion, and more. Advance your career through learning and networking opportunities, and share your experiences in the finance and insurance industries, as well as other fields related to actuarial science.

Description: With more than 24 years of experience in the reinsurance market, Bruno Freire is the CEO and one of the co-founders of Austral Re, along with Vinci Partners, a private equity firm. Austral Re is a Brazilian- based multiline reinsurer which that writes business across Latin America. It has grown organically throughout the last 13 years, and had its credit rating upgraded to A- in 2023 by AM Best (it also has AAAbr from S&P). Before joining Austral, Bruno had been a reinsurance broker at Aon Re for more than 10 years, having witnessed the opening of the reinsurance market in Brazil. As we will be seen in his interview the following, he believes in a data driven analytic approach, client focused but with an underwriting mindset, as well as a strong support from actuaries and technology as key instruments to run a reinsurance company successfully.

Description: This article provides an update, as of September 2019, on the Reinsurance Section’s sponsored research in process and studies recently completed.

Description: Learn from panelists from different companies as they come together to discuss their experiences.

Description: Gather with members and non-members in the China actuarial community to discuss recent topics and related issues in areas such as macroeconomic sharing, pension, investment, product strategy, and more.

Description: This year’s Life Meeting was unable to take place in person as planned in New York City. We are looking forward to the Life Meeting returning to New York City in 2024!